Mentor Capital Cancer Immunotherapy Index Gains 28% During First Quarter of 2013
01 Mai 2013 - 5:41PM
OTC Markets
Mentor Capital, Inc. (Pink Sheets:MNTR) reports that its
proprietary Cancer
Immunotherapy Index appreciated 28.0% during the first quarter of
2013. The
equally weighted Cancer Immunotherapy Index is regularly
benchmarked against
the appreciation of the average of the NASDAQ, S&P, and NYSE
Biotech
Indices. For the first quarter the biotech indices averaged a 15.2%
gain.
Immunocellular Therapeutics (43%), Advaxis (197%) and Celldex
(73%) have led
the sector in gains during the January thru March 2013 period.
Dendreon ($731
Million), Celldex ($718 Million) and Vical ($343 Million) represent
62% of the market
capitalization of the fifteen member Cancer Immunotherapy Index
which has a
combined total share value of $2.9 Billion.
The Mentor Capital Cancer Immunotherapy Index companies and
their performance
for the first thirteen weeks of 2013 follow: Galena Biopharma
Corporation +37.25%,
NewLink Genetics Corporation -1.84%, Vical Incorporated
+36.77%, Inovio Pharmaceuticals, Inc. +19.12%, Dendreon
(NASDAQ:DNDN) -10.49%, Immunocellular Therapeutics, Ltd. (NYSE
MKT:IMUC) +42.71%,
Agenus (NASDAQ:AGEN) -5.12%, Oncothyreon (NASDAQ:ONTY)
+8.07%, Biovest
International (Pink Sheets:BVTIQ) -8.80%, Celldex Therapeutics
(NASDAQ:CLDX) +72.58%,
Northwest Biotherapeutics (NASDAQ:NWBO) +18.60%, CEL – SCI Corp.
(NYSE MKT:CVM)
-14.44% , Generex Biotechnology (OTCBB:GNBT) +24.00% as a proxy for
its
wholly-owned immunotherapeutic subsidiary, Antigen Express,
Provectus Pharmaceuticals,
Inc. (Pink Sheets:PVCT) +30.36% and Advaxis, Inc. (OTCBB:ADXS)
+196.67% - all
for an average 2013 YTD gain of +27.97%. (Annualized rate:
112.20%).
Mentor Capital, Inc., by acquisition or stock
purchase, seeks
to invest in leading-edge private and public cancer companies, and
certain other
situations. Mentor created the Cancer Immunotherapy Index July 10,
2009. Since then, it has invested or maintained a
tracking position in all companies in the Cancer Immunotherapy
Index which can
be found at www.MentorCapital.com.
Forward
Looking Statements, Safe Harbor and Risk
Descriptions are Incorporated by Reference from the MNTR Company
Web Site
above.
For further information contact:
Chester Billingsley,
CEO
Mentor Capital, Inc.
(760) 788 - 4700
Mentor Capital (QB) (USOTC:MNTR)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024
Mentor Capital (QB) (USOTC:MNTR)
Graphique Historique de l'Action
De Juin 2023 à Juin 2024